OmniAb, Inc. (NASDAQ:OABI - Get Free Report) CEO Matthew W. Foehr sold 13,964 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total value of $51,387.52. Following the sale, the chief executive officer now owns 3,798,682 shares in the company, valued at approximately $13,979,149.76. The trade was a 0.37 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
OmniAb Price Performance
NASDAQ OABI traded down $0.23 on Friday, hitting $3.65. 635,557 shares of the stock were exchanged, compared to its average volume of 508,669. The company's 50-day moving average price is $3.49 and its two-hundred day moving average price is $3.91. The company has a market capitalization of $515.45 million, a price-to-earnings ratio of -5.89 and a beta of -0.12. OmniAb, Inc. has a 52-week low of $3.10 and a 52-week high of $6.55.
Analysts Set New Price Targets
Several analysts have weighed in on the stock. Benchmark reiterated a "buy" rating and set a $8.00 target price on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reaffirmed a "buy" rating and set a $11.00 price target on shares of OmniAb in a report on Thursday, November 14th.
Check Out Our Latest Report on OmniAb
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC increased its position in OmniAb by 321.5% during the third quarter. Barclays PLC now owns 143,215 shares of the company's stock worth $606,000 after buying an additional 109,236 shares during the last quarter. FMR LLC boosted its position in OmniAb by 10.6% during the third quarter. FMR LLC now owns 138,813 shares of the company's stock worth $587,000 after purchasing an additional 13,324 shares during the period. Atria Investments Inc acquired a new position in OmniAb during the third quarter valued at approximately $148,000. Murchinson Ltd. bought a new stake in shares of OmniAb during the 3rd quarter worth $4,230,000. Finally, State Street Corp grew its stake in OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company's stock valued at $8,594,000 after buying an additional 34,654 shares during the last quarter. Institutional investors own 72.08% of the company's stock.
About OmniAb
(
Get Free Report)
OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.
Featured Articles
Before you consider OmniAb, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OmniAb wasn't on the list.
While OmniAb currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
